Safety and preliminary evidence of biological efficacy of a mammaglobin-A DNA vaccine in patients with stable metastatic breast cancer

PURPOSE: Mammaglobin-A (MAM-A) is overexpressed in 40–80% of primary breast cancers. We initiated a phase 1 clinical trial of a MAM-A DNA vaccine to evaluate its safety and biological efficacy. EXPERIMENTAL DESIGN: Breast cancer patients with stable metastatic disease were eligible for enrollment. S...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Tiriveedhi, Venkataswarup, Tucker, Natalia, Herndon, John, Li, Lijin, Sturmoski, Mark, Ellis, Matthew, Ma, Cynthia, Naughton, Michael, Lockhart, A. Craig, Gao, Feng, Fleming, Timothy, Goedegebuure, Peter, Mohanakumar, Thalachallour, Gillanders, William E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4322416/
https://ncbi.nlm.nih.gov/pubmed/25451106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-0059
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados